Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 3/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.44 |
| ▸ | MGLL | Q99685 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.34 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | GNE | Q9Y223 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29833344 | 0.84 | HDAC2 (0.51) | HDAC2HDAC1PDCD1CD274MGLL | |
| SCHEMBL12282804 | 0.82 | HDAC1 (0.52) | HDAC2HDAC1PDCD1CD274MGLL | |
| SCHEMBL20775921 | 0.81 | MGLL (0.47) | HDAC2HDAC1PDCD1CD274MGLL | |
| SCHEMBL929672 | 0.77 | PDCD1 (0.43) | HDAC2HDAC1PDCD1CD274MGLL | |
| Hydrochloric Acid SCHEMBL16741194 | 0.76 | PDCD1 (0.43) | HDAC2HDAC1PDCD1CD274MGLL | |
| SCHEMBL20778409 | 0.75 | TDP1 (0.42) | HDAC2HDAC1PDCD1CD274MGLL | |
| Hypochlorous Acid SCHEMBL3087241 | 0.75 | SMO (0.43) | HDAC2HDAC1PDCD1CD274MGLL | |
| SCHEMBL2325818 | 0.75 | WDR5 (0.49) | HDAC2HDAC1TSHRGNEKDM4E | |
| SCHEMBL870351 | 0.74 | HDAC1 (0.45) | HDAC2HDAC1TSHRGNEKDM4E | |
| SCHEMBL27894417 | 0.74 | WDR5 (0.47) | HDAC2HDAC1TSHRGNEKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111295382-B | Bridged bicyclic compounds as farnesyl ester X receptor modulators | 百时美施贵宝公司 | 2024-02-02 | — | — | CN | claimed |
| CN-118678949-A | Novel B0AT1 inhibitors | 田边三菱制药株式会社 | 2024-09-20 | — | — | CN | disclosed |
| CN-118324766-A | Phthalazinone or quinazolinone derivatives, pharmaceutical compositions and uses thereof | 中国科学院上海药物研究所 | 2024-07-12 | — | — | CN | disclosed |
| CN-111050765-B | Spiro compounds and methods of making and using the same | H.隆德贝克有限公司 | 2024-01-02 | — | — | CN | disclosed |
| WO-2023145804-A1 | NOVEL B0AT1 INHIBITOR | 田辺三菱製薬株式会社 | 2023-08-03 | — | — | WO | disclosed |
| CN-113929678-A | ROCK inhibitor and preparation method and application thereof | 武汉朗来科技发展有限公司 | 2022-01-14 | — | — | CN | disclosed |
| CN-111050765-A | Spiro compounds and methods of making and using the same | 隆德贝克拉荷亚研究中心有限公司 | 2020-04-21 | — | — | CN | disclosed |
| EP-2807153-B1 | HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE | NOVARTIS AG (CH) | 2020-03-25 | — | — | EP | disclosed |
| CN-107207504-B | Phthalazinone derivatives, preparation method and use thereof | 四川科伦博泰生物医药股份有限公司 | 2020-03-10 | — | — | CN | disclosed |
| US-9708275-B2 | Heterocyclic compounds and methods for their use | NOVARTIS AG (CH) | 2017-07-18 | — | — | US | disclosed |
| US-20160257656-A1 | HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2016-09-08 | — | — | US | disclosed |
| US-20150011565-A1 | Heterocyclic Compounds and Methods For Their Use | NOVARTIS AG (CH) | 2015-01-08 | — | — | US | disclosed |
| EP-2807153-A1 | HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE | Spinifex Pharmaceuticals Pty Ltd (AU) | 2014-12-03 | — | — | EP | disclosed |
| EP-2791139-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS | Dr. Reddy's Laboratories Ltd. (IN) | 2014-10-22 | — | — | EP | disclosed |
| WO-2013110134-A1 | HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2013-08-01 | — | — | WO | disclosed |
| WO-2013088257-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2013-06-20 | — | — | WO | disclosed |
| EP-2085398-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | Merz Pharma GmbH & Co. KGaA (DE) | 2009-08-05 | — | — | EP | disclosed |
| WO-2009050236-A1 | NOVEL PIPERAZINO-DIHYDROTHIENOPYRIMIDINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
| US-20060052382-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052382-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | HDAC2 1929/4885HDAC1 2882/4885PDCD1 2968/4885 |
| US-20160257656-A1 | HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE | AGTR2, AGTR1, BDKRB2 | HDAC2 660/4885HDAC1 1390/4885PDCD1 2979/4885 |
| US-20150011565-A1 | Heterocyclic Compounds and Methods For Their Use | AGTR2, AGTR1, BDKRB2 | HDAC2 699/4885HDAC1 1403/4885PDCD1 3016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.